Tag:
AYO Technology
Ghost Bites
GHOST BITES (AECI | Altvest | Merafe | MTN | Northam Platinum | Primary Health Properties | Sabvest | Safari Investments | Thungela)
Merafe, MTN, Northam Platinum, Primary Health Properties, Sabvest, Safari Investments and Thungela all released numbers. AECI announced a B-BBEE deal. Altvest has raised debt capital in ACOF.
DealMakers
Weekly corporate finance activity by SA exchange-listed companies
Weekly summary of corporate finance activity by South African exchange listed companies
Ghost Bites
GHOST BITES (AB InBev | AECI | Barloworld | Bidcorp | Hammerson | Momentum | Oceana)
Barloworld shareholders shunned the scheme. Alcohol volumes still dropping at AB InBev. AECI hopes to have turned the corner. Bidcorp and Momentum released strong numbers. Hammerson and Oceana had recent struggles.
Ghost Bites
GHOST BITES (Aveng | Jubilee Metals | Metair)
Aveng shareholders are licking their wounds. Jubilee is trying to catch up lost production at Roan. Metair is making major strategic changes in its business, but that balance sheet looks frightening.
Ghost Bites
GHOST BITES (Capitec | Gemfields | Nampak | Spar | Truworths)
Capitec keeps on pumping. Truworths released awful local numbers. Nampak achieved another turnaround milestone. Spar has gotten rid of Poland at last. Gemfields desperately needs things to improve.
Ghost Bites
GHOST BITES (Afrimat | Karooooo | Stor-Age)
Afrimat has completed the integration of Lafarge. Karooooo reported another strong set of numbers, although margins must always be watched. Stor-Age is expanding the Parklands facility.
Ghost Bites
GHOST BITES (Aspen | Metair | Rex Trueform | Sanlam | Sasfin)
Aspen is bringing Eli Lilly's Ozempic competitor to the SA market. Metair is getting even less from the Mutlu disposal than we thought. Rex Trueform is buying a software group at a huge multiple. Sanlam unlocked billions from Allianz. Sasfin is delisting this month.
Ghost Bites
GHOST BITES (Italtile | Nictus | Sibanye-Stillwater | Transaction Capital)
Italtile's share price momentum makes no sense to me. Sibanye-Stillwater has pulled off a sensible uranium deal. Transaction Capital's results are delayed. Nictus had a terrific year thanks to investment income.
